34712126|t|A Single Low Dose of Dexmedetomidine Efficiently Attenuates Esketamine-Induced Overactive Behaviors and Neuronal Hyperactivities in Mice.
34712126|a|Introduction: Esketamine (Esk) (S(+)-ketamine) is now used as an alternative to its racemic mixture, i. e., ketamine in anesthesia. Esk demonstrated more powerful potency and rapid recovery in anesthesia and less psychotomimetic side effects comparing with ketamine, but Esk could still induce psychological side effects in patients. This study was to investigate whether dexmedetomidine (Dex) can attenuate the Esk-induced neuronal hyperactivities in Kunming mice. Methods: Dexmedetomidine 0.25, 0.5, and 1 mg/kg accompanied with Esk 50 mg/kg were administrated on Kunming mice to assess the anesthesia quality for 1 h. The indicators, such as time to action, duration of agitation, duration of ataxia, duration of loss pedal withdrawal reaction (PWR), duration of catalepsy, duration of righting reflex (RR) loss, duration of sedation, were recorded for 1 h after intraperitoneal administration. The c-Fos expression in the brain was detected by immunohistochemistry and Western Blot after 1 h of administration. Considering the length of recovery time for more than 1 h in Dex and Dex with Esk groups, other mice were repeatedly used to evaluate recovery time from the administration to emerge from anesthesia. Results: Dexmedetomidine dose-dependently increased recovery time when administrated with Esk or alone. Dex combined with Esk efficiently attenuated the duration of agitation, ataxia, and catalepsy. Dex synergically improved the anesthesia of Esk by increasing the duration of sedation, loss of RR, and loss of PWR. Esk induced the high expression of c-Fos in the cerebral cortex, hippocampus, thalamus, amygdala, hypothalamus, and cerebellum 1 h after administration. Western Blot results indicated that Dex at doses of 0.25, 0.5, and 1 mg/kg could significantly alleviate the Esk-induced c-Fos expression in the mice brain. Conclusion: Dexmedetomidine ranged from 0.25 to 1 mg/kg could improve the anesthesia quality and decreased the neuronal hyperactivities and the overactive behaviors when combined with Esk. However, Dex dose-dependently increased the recovery time from anesthesia. It demonstrated that a small dose of Dex 0.25 mg/kg could be sufficient to attenuate Esk-induced psychotomimetic side effects without extension of recovery time in Kunming mice.
34712126	21	36	Dexmedetomidine	Chemical	MESH:D020927
34712126	60	70	Esketamine	Chemical	MESH:C000629870
34712126	79	99	Overactive Behaviors	Disease	MESH:D053201
34712126	104	128	Neuronal Hyperactivities	Disease	MESH:D001289
34712126	132	136	Mice	Species	10090
34712126	152	162	Esketamine	Chemical	MESH:C000629870
34712126	164	167	Esk	Chemical	MESH:C000629870
34712126	170	183	S(+)-ketamine	Chemical	MESH:C000629870
34712126	246	254	ketamine	Chemical	MESH:C000629870
34712126	270	273	Esk	Chemical	MESH:C000629870
34712126	351	366	psychotomimetic	Disease	
34712126	395	403	ketamine	Chemical	MESH:C000629870
34712126	409	412	Esk	Chemical	MESH:C000629870
34712126	462	470	patients	Species	9606
34712126	510	525	dexmedetomidine	Chemical	MESH:D020927
34712126	527	530	Dex	Chemical	MESH:D020927
34712126	550	553	Esk	Chemical	MESH:C000629870
34712126	562	586	neuronal hyperactivities	Disease	MESH:D001289
34712126	598	602	mice	Species	10090
34712126	613	628	Dexmedetomidine	Chemical	MESH:D020927
34712126	669	672	Esk	Chemical	MESH:C000629870
34712126	712	716	mice	Species	10090
34712126	811	820	agitation	Disease	MESH:D011595
34712126	834	840	ataxia	Disease	MESH:D001259
34712126	904	913	catalepsy	Disease	MESH:D002375
34712126	1040	1045	c-Fos	Gene	14281
34712126	1214	1217	Dex	Chemical	MESH:D020927
34712126	1222	1225	Dex	Chemical	MESH:D020927
34712126	1231	1234	Esk	Chemical	MESH:C000629870
34712126	1249	1253	mice	Species	10090
34712126	1361	1376	Dexmedetomidine	Chemical	MESH:D020927
34712126	1442	1445	Esk	Chemical	MESH:C000629870
34712126	1456	1459	Dex	Chemical	MESH:D020927
34712126	1474	1477	Esk	Chemical	MESH:C000629870
34712126	1517	1526	agitation	Disease	MESH:D011595
34712126	1528	1534	ataxia	Disease	MESH:D001259
34712126	1540	1549	catalepsy	Disease	MESH:D002375
34712126	1551	1554	Dex	Chemical	MESH:D020927
34712126	1595	1598	Esk	Chemical	MESH:C000629870
34712126	1639	1649	loss of RR	Disease	MESH:C000721448
34712126	1655	1666	loss of PWR	Disease	MESH:D013375
34712126	1668	1671	Esk	Chemical	MESH:C000629870
34712126	1703	1708	c-Fos	Gene	14281
34712126	1857	1860	Dex	Chemical	MESH:D020927
34712126	1930	1933	Esk	Chemical	MESH:C000629870
34712126	1942	1947	c-Fos	Gene	14281
34712126	1966	1970	mice	Species	10090
34712126	1990	2005	Dexmedetomidine	Chemical	MESH:D020927
34712126	2089	2113	neuronal hyperactivities	Disease	MESH:D001289
34712126	2122	2142	overactive behaviors	Disease	MESH:D053201
34712126	2162	2165	Esk	Chemical	MESH:C000629870
34712126	2176	2179	Dex	Chemical	MESH:D020927
34712126	2279	2282	Dex	Chemical	MESH:D020927
34712126	2327	2330	Esk	Chemical	MESH:C000629870
34712126	2339	2354	psychotomimetic	Disease	
34712126	2414	2418	mice	Species	10090
34712126	Positive_Correlation	MESH:C000629870	MESH:D001289
34712126	Negative_Correlation	MESH:C000629870	MESH:D002375
34712126	Negative_Correlation	MESH:C000629870	MESH:D020927
34712126	Negative_Correlation	MESH:D020927	MESH:D053201
34712126	Negative_Correlation	MESH:C000629870	MESH:D001259
34712126	Negative_Correlation	MESH:D020927	MESH:D001289
34712126	Negative_Correlation	MESH:D020927	MESH:C000721448
34712126	Negative_Correlation	MESH:C000629870	MESH:D011595
34712126	Negative_Correlation	MESH:D020927	MESH:D001259
34712126	Positive_Correlation	MESH:D020927	MESH:D013375
34712126	Positive_Correlation	MESH:C000629870	MESH:D053201
34712126	Negative_Correlation	MESH:D020927	MESH:D002375
34712126	Negative_Correlation	MESH:D020927	MESH:D011595

